Molecular characterization of low grade and high grade bladder cancer

Alessandro Apollo, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Paolo Aretini, Francesca Lessi, Sara Franceschi, Sara Tomei, Carlo Alberto Sepich, Paolo Viacava, Chiara Maria Mazzanti, Antonio Giuseppe Naccarato

Research output: Contribution to journalArticle

Abstract

Background Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). Conclusion We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.

Original languageEnglish
Article numbere0210635
JournalPLoS One
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Urinary Bladder Neoplasms
Tumors
Biomarkers
Gene expression
neoplasms
biomarkers
Neoplasms
Histology
Cadherins
Gene Expression
gene expression
therapeutics
cadherins
histology
Cluster Analysis
Recurrence
urinary bladder neoplasms
Therapeutics
methodology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Apollo, A., Ortenzi, V., Scatena, C., Zavaglia, K., Aretini, P., Lessi, F., ... Naccarato, A. G. (2019). Molecular characterization of low grade and high grade bladder cancer. PLoS One, 14(1), [e0210635]. https://doi.org/10.1371/journal.pone.0210635

Molecular characterization of low grade and high grade bladder cancer. / Apollo, Alessandro; Ortenzi, Valerio; Scatena, Cristian; Zavaglia, Katia; Aretini, Paolo; Lessi, Francesca; Franceschi, Sara; Tomei, Sara; Sepich, Carlo Alberto; Viacava, Paolo; Mazzanti, Chiara Maria; Naccarato, Antonio Giuseppe.

In: PLoS One, Vol. 14, No. 1, e0210635, 01.01.2019.

Research output: Contribution to journalArticle

Apollo, A, Ortenzi, V, Scatena, C, Zavaglia, K, Aretini, P, Lessi, F, Franceschi, S, Tomei, S, Sepich, CA, Viacava, P, Mazzanti, CM & Naccarato, AG 2019, 'Molecular characterization of low grade and high grade bladder cancer', PLoS One, vol. 14, no. 1, e0210635. https://doi.org/10.1371/journal.pone.0210635
Apollo A, Ortenzi V, Scatena C, Zavaglia K, Aretini P, Lessi F et al. Molecular characterization of low grade and high grade bladder cancer. PLoS One. 2019 Jan 1;14(1). e0210635. https://doi.org/10.1371/journal.pone.0210635
Apollo, Alessandro ; Ortenzi, Valerio ; Scatena, Cristian ; Zavaglia, Katia ; Aretini, Paolo ; Lessi, Francesca ; Franceschi, Sara ; Tomei, Sara ; Sepich, Carlo Alberto ; Viacava, Paolo ; Mazzanti, Chiara Maria ; Naccarato, Antonio Giuseppe. / Molecular characterization of low grade and high grade bladder cancer. In: PLoS One. 2019 ; Vol. 14, No. 1.
@article{2b05bd9f519c45dd8b333174d787251e,
title = "Molecular characterization of low grade and high grade bladder cancer",
abstract = "Background Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70{\%} of all BCs, characterized by recurrence and rare ability (10–15{\%}) to progress to high grade (HG) and invade. The remaining 30{\%} is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). Conclusion We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.",
author = "Alessandro Apollo and Valerio Ortenzi and Cristian Scatena and Katia Zavaglia and Paolo Aretini and Francesca Lessi and Sara Franceschi and Sara Tomei and Sepich, {Carlo Alberto} and Paolo Viacava and Mazzanti, {Chiara Maria} and Naccarato, {Antonio Giuseppe}",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0210635",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Molecular characterization of low grade and high grade bladder cancer

AU - Apollo, Alessandro

AU - Ortenzi, Valerio

AU - Scatena, Cristian

AU - Zavaglia, Katia

AU - Aretini, Paolo

AU - Lessi, Francesca

AU - Franceschi, Sara

AU - Tomei, Sara

AU - Sepich, Carlo Alberto

AU - Viacava, Paolo

AU - Mazzanti, Chiara Maria

AU - Naccarato, Antonio Giuseppe

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). Conclusion We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.

AB - Background Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). Conclusion We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=85060114330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060114330&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0210635

DO - 10.1371/journal.pone.0210635

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0210635

ER -